SCOPUS 정보 검색 플랫폼

Volumn 40, Issue 6, 2017, Pages e65-e66

Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis: A case series from three academic institutions

(7) Misaghian Xanthos, Negin a Shariff, Afreen I b Mekala, Kavya c Fearrington, Loretta R a Setji, Tracy L b Aloi, Joseph A c Buse, John B a

a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE (United States)

b DUKE UNIVERSITY SCHOOL OF MEDICINE (United States)

c WAKE FOREST SCHOOL OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; KETONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ARTERIAL PH; BICARBONATE BLOOD LEVEL; BLOOD LEVEL; CASE STUDY; DIABETIC KETOACIDOSIS; DISEASE PREDISPOSITION; ELECTRONIC HEALTH RECORD; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; KETONE BLOOD LEVEL; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PRACTICE GUIDELINE; PRESCRIPTION; SHORT SURVEY; VOMITING; WEIGHT REDUCTION;

EID: 85019705692 PISSN: 01495992 EISSN: 19355548 Source Type: Journal
DOI: 10.2337/dc16-2591 Document Type: Short Survey

Times cited : (18)

References (4)

1
- 84962339296
- Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
- Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693
- (2015) Diabetes Care , vol.38 , pp. 1687-1693
- Peters, A.L.¹ Buschur, E.O.² Buse, J.B.³ Cohan, P.⁴ Diner, J.C.⁵ Hirsch, I.B.⁶

2
- 84964571863
- U.S. Food and Drug Administration, [Internet], 4 December. Accessed 17 November 2016
- U.S. Food and Drug Administration. SGLT2 inhibitors: drug safety communication-labels to include warnings about too much acid in the blood and serious urinary tract infections [Internet], 4 December 2015. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ ucm475553.htm. Accessed 17 November 2016
- (2015) SGLT2 Inhibitors: Drug Safety Communication-labels to Include Warnings about Too Much Acid in the Blood and Serious Urinary Tract Infections

3
- 84962381148
- Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program
- Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015;38:1680-1686
- (2015) Diabetes Care , vol.38 , pp. 1680-1686
- Erondu, N.¹ Desai, M.² Ways, K.³ Meininger, G.⁴

4
- 84962439093
- Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors
- Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642
- (2015) Diabetes Care , vol.38 , pp. 1638-1642
- Rosenstock, J.¹ Ferrannini, E.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.